Reported about 20 hours ago
Stifel has maintained its 'Buy' rating for Compass Therapeutics (NASDAQ:CMPX) with a price target of $11, following meetings with the company's management. The firm views the extended timeline for overall survival data in the Phase 2/3 COMPANION-002 trial as a positive sign, given the poor survival rates for control patients. Additionally, upcoming data releases for other compounds in late 2025 may serve as crucial catalysts for the company.
Source: YAHOO